Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.35 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2207598 | 0.87 | ELANE (0.38) | ELANEERCC1ERCC5FEN1ERCC4 | |
| SCHEMBL5613245 | 0.84 | TDP1 (0.41) | ELANEERCC1ERCC5FEN1ERCC4 | |
| SCHEMBL2207892 | 0.83 | HSD17B10 (0.39) | ELANEERCC1ERCC5FEN1ERCC4 | |
| SCHEMBL1523092 | 0.80 | ALDH1A1 (0.42) | ELANEERCC1ERCC5FEN1ERCC4 | |
| SCHEMBL1523116 | 0.79 | ERCC1 (0.34) | ELANEERCC1ERCC5FEN1ERCC4 | |
| SCHEMBL1523762 | 0.78 | ERCC5 (0.57) | ERCC1ERCC5FEN1ERCC4ADORA2B | |
| SCHEMBL23412821 | 0.77 | ELANE (0.36) | ELANEADORA2B | |
| SCHEMBL1522426 | 0.76 | FEN1 (0.45) | ELANEERCC1ERCC5FEN1ERCC4 | |
| SCHEMBL3922160 | 0.76 | KMT2A (0.44) | ERCC1ERCC5FEN1ERCC4PDE1B | |
| SCHEMBL5616743 | 0.73 | ELANE (0.34) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7982040-B2 | Thienopyridinone compounds and methods of treatment | NANOTHERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7576211-B2 | Synthesis of thienopyridinone compounds and related intermediates | EPIX DELAWARE, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090163537-A1 | Thienopyridinone Compounds and Methods of Treatment | NANOSHIFT, LLC | 2009-06-25 | — | — | US | disclosed |
| US-7488736-B2 | Thienopyridinone compounds and methods of treatment | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20060084805-A1 | Synthesis of thienopyridinone compounds and related intermediates | NANOSHIFT, LLC | 2006-04-20 | — | — | US | disclosed |
| US-20050256153-A1 | Thienopyridinone compounds and methods of treatment | NANOSHIFT, LLC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163537-A1 | Thienopyridinone Compounds and Methods of Treatment | HTR5A, GIPR, TBXA2R | ELANE 1738/4885ERCC1 1777/4885ERCC5 1966/4885 |
| US-20060084805-A1 | Synthesis of thienopyridinone compounds and related intermediates | HTR5A, GIPR, HTR1A | ELANE 2186/4885ERCC1 1642/4885ERCC5 1759/4885 |
| US-20050256153-A1 | Thienopyridinone compounds and methods of treatment | HTR5A, GIPR, TBXA2R | ELANE 1738/4885ERCC1 1777/4885ERCC5 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.